Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 318

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 318
---
 $9.90    -    -   Options exercised   (108,000)  $3.91    -    -   Outstanding at December 31, 2024   7,203,307   $8.29    6.49   $1,218   Exercisable at December 31, 2024   4,988,685   $8.68    5.20   $1,218  

F-16

During the years ended December 31, 2024 and 2023, the Company
recognized stock-based compensation expense of $7,605,000 and $7,368,000, respectively, related to stock options. As of December 31,
2023, there was $12,213,000 of total unrecognized compensation cost related to non-vested stock options which is expected to be recognized
over a weighted-average period of 2.37 years.

Warrants

The Company issued warrants to the Company’s
lenders upon obtaining a loan in June 2021. The warrants have a 10-year term and an exercise price of $14.05. At December 31, 2024
and 2023, respectively, 45,386 of these warrants are outstanding and the intrinsic value of these warrants is $0.

During April
2024, the Company issued 1,557,592 warrants to investors in connection with the sale of common stock. At December 31, 2024, 1,557,592 of
these warrants are outstanding and are exercisable for cash at a weighted average price of $9.59 per share. The intrinsic value of
these warrants was $0 as of December 31, 2024.

During September
2024, the Company issued 2,341,260 warrants to investors in connection with the sale of common stock. At December 31, 2024, 2,341,260 of
these warrants are outstanding and are exercisable for cash at a weighted average price of $6.40 per share. The intrinsic value of
these warrants was $0 as of December 31, 2024.

During the year ended December 31, 2023, a third
party exercised 28,688 warrants on a cashless basis in exchange for 4,781 shares of common